|Articles|May 4, 2020

COVID-19: Navigating Remdesivir Results & Institutional Inertia

Cornelius J. Clancy, MD, discusses navigating partial trial information and the need for coherent national coordination on the COVID-19 response.

Segment Description: Cornelius J. Clancy, MD, discusses navigating partial trial information and the need for coherent national coordination on the COVID-19 response.


Related to this article

New Diagnositics for Legionella Pneumonia May Streamline Care Continuum
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
REMAP-CAP and the Tamiflu “Pre-Release”: A Set-Up for Disaster
Preliminary REMAP-CAP data suggesting oseltamivir may increase mortality in critically ill ICU influenza patients has sparked polarized reactions, but clinicians should await the full peer-reviewed manuscript before drawing broad conclusions, since the signal comes from a narrow, severely ill population and may reflect a therapeutic window effect rather than a blanket lack of efficacy.